The EPS and revenue miss, combined with a slow prescription launch trajectory (1,500 scripts in ~4.5 months), suggest the market may reprice expectations for CARDAMYST adoption. Monitor the upcoming investor call for updated 2026 revenue guidance and prescription trends through Q3. The post-quarter coverage expansion to ~50% of lives is a positive catalyst that could accelerate scripts, but the stock may trade down initially on the headline miss.
Price Chart
Executive Summary
Milestone Pharmaceuticals reported Q2 2026 results with product revenue of $0.6M, up from zero a year ago, but net loss widened to $28.6M ($0.21/share) vs $13.0M ($0.20/share) as launch costs for CARDAMYST ramped. The EPS of -$0.21 missed consensus of -$0.19 by 9.1%, while revenue of $0.6M missed the $817K estimate. The stock will move on the EPS miss and the slower-than-expected prescription ramp (1,500 scripts through June vs ~300 at Q1 end), partially offset by the significant expansion of commercial coverage to ~50% of lives from ~25% post-quarter end.
Key Financial Metrics
Key Facts
- Q2 2026 product revenue $0.6M (vs $0 in Q2 2025), below consensus of $817K
- EPS -$0.21 missed consensus of -$0.19 (-9.1% miss)
- Net loss widened to $28.6M from $13.0M YoY, driven by $22.6M in SG&A (launch costs)
- 1,500 scripts filled through June 30, up from ~300 at Q1 end; 800+ unique prescribers
- Commercial coverage expanded to ~50% of U.S. lives post-quarter (from ~25% at Q2 end)
- Cash, equivalents, and short-term investments of $170.6M provide runway into H2 2027
- Phase 3 ReVeRA-301 trial in AFib-RVR sites activated; first patient enrollment on track for H2 2026
Financial Impact
EPS miss of 9.1% on a -$0.21 actual vs -$0.19 consensus; revenue miss of ~27% ($0.6M vs $817K consensus); net loss $28.6M vs $13.0M YoY
Risk Factors
- Slower-than-expected CARDAMYST prescription growth despite coverage expansion
- Cash burn rate of ~$28M/quarter implies ~6 quarters of runway, may require additional financing before H2 2027
- Phase 3 AFib-RVR trial enrollment delays or negative data
- European MAA decision not expected until H1 2027, no near-term catalyst
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-094466 |
| Document: tm2614433d1_8k.htm | 0001104659-26-094466 |
| Document: 0001104659-26-094466-index-headers.html | 0001104659-26-094466 |
| Document: 0001104659-26-094466-index.html | 0001104659-26-094466 |
| Document: 0001104659-26-094466.txt | 0001104659-26-094466 |
| 8-K Data (Synthetic) | 0001104659-26-094466 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 7w ago | 8-K | $1.20 $0.7794 | ▼ −35.05% | ▼ −35.65% | $0.6444 (−46.30%) |
Aug 21, 2026 9w ago | Press Release | $1.06 $0.9178 | ▼ −13.00% | ▼ −12.48% | $0.6444 (−38.92%) |
Aug 12, 2026 10w ago | 8-K | $1.13 $1.05 | ▲ +6.67% | ▲ +4.77% | $0.6444 (+42.72%) |
May 26, 2026 21w ago | EFFECT | $1.40 $1.28 | ▲ +8.57% | ▲ +6.62% | $0.6444 (+53.97%) |
May 13, 2026 23w ago | S-3 | $1.63 $1.27 | ▲ +22.09% | ▲ +21.23% | $0.6444 (+60.47%) |
May 13, 2026 23w ago | 8-K | $1.72 $1.27 | ▼ −26.16% | ▼ −25.55% | $0.6444 (−62.53%) |
May 13, 2026 23w ago | Press Release | $1.72 $1.27 | ▼ −26.16% | ▼ −25.55% | $0.6444 (−62.53%) |
Mar 20, 2026 31w ago | Press Release | $1.36 $2.04 | ▲ +50.00% | ▲ +40.68% | $0.6444 (−52.62%) |
Mar 16, 2026 32w ago | Press Release | $1.69 $2.03 | ▲ +20.12% | ▲ +16.34% | $0.6444 (−61.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers